Tin tức & Cập nhật

Finerenone significantly reduces albuminuria vs placebo and maintains a manageable safety profile in patients with type 1 diabetes (T1D) and chronic kidney disease (CKD) receiving background therapy with renin-angiotensin-aldosterone system inhibitors (RAASi), the phase III FINE-ONE trial has shown. These findings represent an important step forward since RAASi were introduced for renoprotection in T1D more than 30 years ago.

A study from Israel presented at ELCC 2026 supports the role of glucose control as a modifiable host factor that could improve the effectiveness of immune checkpoint inhibitors in the treatment of non-small cell lung cancer (NSCLC).